Evaluation of serum CEA and CA19-9 levels as prognostic factors in patients with gastric cancer

被引:130
|
作者
Kochi M. [1 ]
Fujii M. [1 ]
Kanamori N. [1 ]
Kaiga T. [1 ]
Kawakami T. [1 ]
Aizaki K. [1 ]
Kasahara M. [1 ]
Mochizuki F. [1 ]
Kasakura Y. [1 ]
Yamagata M. [1 ]
机构
[1] Third Department of Surgery, Nihon University School of Medicine, Itabashi-ku, Tokyo 173-8610
关键词
CA19-9; CEA; Gastric cancer; Prognosis; Tumor marker;
D O I
10.1007/PL00011715
中图分类号
学科分类号
摘要
Background. This clinicopathological study evaluated the utility of serum carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) 19-9 as predictors of locoregional recurrence and long-term disease-free survival in patients with gastric cancer. Methods. During the period January 1989 to December 1994, 485 patients with primary gastric cancer were evaluated. Gastrectomies were performed in 434 patients. Prognostic factors were analyzed by the Kaplan-Meier method and multivariate analysis, using Cox regression. Results. Elevated serum CEA and CA19-9 levels were observed in 92 of the 485 patients (19.0%), and in 95 of the 435 patients (21.8%), respectively, and both markers were elevated in 29 of these 435 patients (6.7%). Elevated serum CEA and CA19-9 levels correlated well with lymph node metastasis, lymphatic invasion, vessel invasion, stage grouping, depth of invasion, and curability. Patients with elevated serum CEA levels were at significantly higher risk of having all recurrence factors than were those with normal serum CEA levels. Patients with elevated serum CA19-9 levels were at significantly higher risk of having peritoneal metastases and distant metastases than were those with normal serum CA19-9 levels. A significant difference in the cumulative survival curves of patients was demonstrated between those with elevated and those with normal serum CEA or CA19-9 levels, even for patients at the same disease stage (stage III). Patients with elevated levels of both markers had a significantly worse prognosis than patients in whom the levels of both markers were normal. In patients who underwent gastrectomy, elevated serum CEA levels either preoperatively or within 3 weeks after gastrectomy were associated with significantly worse prognosis than were normal levels. When the cutoff level of serum CEA was increased to 10ng/ml, serum CEA, age, lymph node metastasis, and surgical stage grouping were selected as independent prognostic factors by multivariate analysis of 14 prognostic factors, using Cox regression. Conclusion. Serum CEA and CA19-9 levels provide additional prognostic information in patients with primary gastric cancer. In particular, an elevated serum CEA level provides additional prognostic information and is a useful indicator of curability in patients who undergo gastrectomy. Serum CEA level is an independent prognostic factor in patients with primary gastric cancer.
引用
收藏
页码:177 / 186
页数:9
相关论文
共 50 条
  • [21] Clinical significance and prognostic value of CA72-4 compared with CEA and CA19-9 in patients with gastric cancer
    Ychou, M
    Duffour, J
    Kramar, A
    Gourgou, S
    Grenier, J
    DISEASE MARKERS, 2000, 16 (3-4) : 105 - 110
  • [22] Early postoperative tumor markers (CEA, CA19-9, TAG 72) levels in patients with gastric cancer
    Roviello, F
    Marrelli, D
    Farnetani, M
    Garosi, L
    DeStefano, A
    Messano, A
    Pinto, E
    PROGRESS IN GASTRIC CANCER RESEARCH 1997: PROCEEDINGS OF THE 2ND INTERNATIONAL GASTRIC CANCER CONGRESS, 1997, : 1699 - 1702
  • [23] Diagnostic and Prognostic Value of CEA and CA19-9 in Colorectal Cancer
    Lakemeyer, Leilani
    Sander, Silvia
    Wittau, Mathias
    Henne-Bruns, Doris
    Kornmann, Marko
    Lemke, Johannes
    DISEASES, 2021, 9 (01)
  • [24] The Changes and Clinical Significance of Preoperative and Postoperative Serum CEA and CA19-9 in Gastric Cancer
    Jing, Rongrong
    Cui, Ming
    Ju, Shaoqing
    Pan, Shiyang
    CLINICAL LABORATORY, 2020, 66 (04) : 569 - 577
  • [25] Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence
    Lai, IR
    Lee, WJ
    Huang, MT
    Lin, HH
    HEPATO-GASTROENTEROLOGY, 2002, 49 (46) : 1157 - 1160
  • [26] Diagnostic and prognostic value of CEA, CA19-9, AFP and CA125 for early gastric cancer
    Feng, Fan
    Tian, Yangzi
    Xu, Guanghui
    Liu, Zhen
    Liu, Shushang
    Zheng, Gaozan
    Guo, Man
    Lian, Xiao
    Fan, Daiming
    Zhang, Hongwei
    BMC CANCER, 2017, 17
  • [27] A clinical study of colorectal cancer patients associated with the serum CEA and CA19-9
    Horie, T.
    ANNALS OF ONCOLOGY, 2007, 18 : VII78 - VII78
  • [28] Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer
    Liang, Yao
    Wang, Wei
    Fang, Cheng
    Raj, Seeruttun Sharvesh
    Hu, Wan-Ming
    Li, Qi-Wen
    Zhou, Zhi-Wei
    ONCOTARGET, 2016, 7 (31) : 49565 - 49573
  • [29] Clinical significance of serum LDH, CEA and CA19-9 levels in metastatic pancreatic cancer
    Karabulut, S.
    Ciftci, R.
    Sen, F.
    Tas, F.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S601 - S602
  • [30] Change of serum CEA or CA19-9 is predictive for chemotherapeutic efficacy in recurrence or metastasis gastric cancer
    Shen, L.
    Lu, Q. Y.
    Lu, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)